Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D01931 (
TiO2
)
11,320
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Osteosarcoma
and chondrosarcoma are malignant bone tumors, and they significantly affect the life quality of patients including children and adults. The main treatment method is surgical amputation of the malignant lesion, despite that recurrence often occurs. Recently, it has been observed that
TiO2
NPs killed HeLa cells effectively via photocatalysis in vitro, which indicates titanium dioxide (
TiO2
) nanoparticles (NPs) might be used to reduce the recurrence of osteosarcoma and chondrosarcoma by inducing cytotoxicity to bone tumor cells. In this study, we investigated the potential effects of
TiO2
NPs in two cancer cell lines in vitro: U-2 OS (osteosarcoma) and SW 1353 (chondrosarcoma). We assessed cell viability, the levels of reactive oxygen species (ROS) and glutathione (GSH) after exposure to
TiO2
NPs at different concentrations (0.1-100 microg/ml) for varying exposure periods (12-48 hours). Compared to the NP-free control,
TiO2
NPs induced cell death in a dosage-dependent and time-dependent manner. The median inhibitory concentration (IC50) of
TiO2
NPs at 24 hours was 211.3 +/- 15.2 microg/ml and 5408.8 +/- 45.9 microg/ml for SW 1353 and U-2 OS cell lines, respectively.
TiO2
NPs concentrations above 1 microg/ml were more efficient to reduce the cell viability of SW 1353 than U-2 OS of NPs at all exposure times. The increased ROS and reduced GSH levels indicated that
TiO2
NPs killed cancer cells through oxidative stress. These results suggested that the
TiO2
NPs can be potentially used to minimize/prevent the recurrence of osteosarcoma and chondrosarcoma.
...
PMID:Potential application of titanium dioxide nanoparticles in the prevention of osteosarcoma and chondrosarcoma recurrence. 2364 4